In a randomized phase II clinical trial, researchers investigated the efficacy of combining afatinib (a tyrosine kinase inhibitor) with cetuximab (a monoclonal antibody) in previously untreated patients with EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.